Green Health Advocates: Has America Gone Kratom? CBD is Cool But Maybe More Trendy Competitors Exist
March 08 2017 - 8:39AM
PR Newswire (Canada)
Breaking news on green health stock companies on the rise
while developing super drugs made from cannabidiol and
kratom
TORONTO, March 8, 2017 /CNW/ - Green Health
Advocates shares its thoughts on the recent news
release by Health Advance, Inc. (OTC PINK: HADV) ,
a macro-cap company that announced its plans on development of the
first FDA regulated pharmaceutical food over the next two months
with the support of a research organization that has been
responsible for assisting the clinical studies and product testing
for medical foods and pre-approved drugs that are in phase three-
basically known as the final testing phase before any form of
medicine can legitimize under federal laws
Mitragyna speciosa (known as kratom) had a brief
omnipresence on Wall Street until Fall 2014 when Sigma-Aldrich
Corporation, a U.S. based bio-tech company that developed
kratom alkaloid solutions was quickly acquired by Merck Group
(Merck KGaA), a German big pharm company
for $17 billion. Apparently its taken a few years medicine
developers to resurface kratom efforts on Wall
Street. The patent-pending polyoxyfen product
formulation appears to be the first pharmaceutical food derived
from the Mitragyna speciosa plant to receive a medical or
nutritional study by a credible research expert agency. Luckily for
HADV's motives to shoot for a medical food opposed to a new drug
application, they'd potentially be legal in the national healthcare
marketplace before the end of the year if they meet GRAS
(Generally Recognized As Safe) regulatory requirements at
FDA..
In the opinion of research experts, Health Advance does not appear
to be light years behind more established bio-pharmaceutical
companies like GW Pharmaceuticals (NASDAQ: GWPH) , a developer
for plant-derived cannabinoid therapeutics. GW Pharmaceuticals has
successfully developed [Sativex] the world's first prescription
medicine made from the cannabis plant. Unlike GWPH's Sativex that
is legally available in 29 countries, Health Advance's recent
product formulation patent-pending license acquisition of
cebidiofen would be the first pharmaceutics product derived from
the cannabis plant that could possibly pass GRAS regulatory
standards in the United States and Canada --
potentially other countries where GW Pharms has already pioneered a
path for CBD-NSAID related drugs.
Green Health Advocates has created a presence on social
media and news blogs to provide research updates and product
information on organic medicine and dietary supplements to
potential consumers and investors.
Article By: Green Health Advocates
SOURCE Green Health Advocates
Copyright 2017 Canada NewsWire
GW Pharmaceuticals (NASDAQ:GWPH)
Historical Stock Chart
From Apr 2024 to May 2024
GW Pharmaceuticals (NASDAQ:GWPH)
Historical Stock Chart
From May 2023 to May 2024